Opportunistic Infections clinical trials

The registry lists 41 studies for Opportunistic Infections across more than 10 countries. 12 are recruiting or about to start. 10 of them are mainly about Opportunistic Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as AIDS-Related Opportunistic Infections: 250 studies, 16 open.

Get an email when these change. Save the Opportunistic Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 22
Recruiting: 8
Not yet recruiting: 4
Active, not recruiting: 3
Status unknown: 2
Terminated: 1

Phase

Phase 2: 8
Phase 4: 5
Phase 1: 4
Phase 3: 3
Early Phase 1: 2

Where

United States: 17
China: 4
South Africa: 3
Thailand: 3
Russian Federation: 2
India: 2

Who runs them

National Institute of Allergy and Infectious Diseases (NIAID) (7) · National Cancer Institute (NCI) (6) · Mari Dallas (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · University of Bergen (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · National Eye Institute (NEI) (1) · Shanghai Public Health Clinical Center (1)

What is being tested here

Drugs under test in Opportunistic Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Sintilimab	1	0	1
Mycophenolic Acid	0	1	2
Antilymphocyte Serum	0	0	1
Busulfan	0	0	1
Prednisone	0	0	1
Cyclophosphamide	0	0	1
Mesna	0	0	1
Tacrolimus	0	0	1
Pentostatin	0	0	1
Zidovudine	0	0	1

Coming up

0phase 3 studies under way

3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Nov 2026A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia · National Institute of Allergy and Infectious Diseases (NIAID)
Jun 2027Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma · National Cancer Institute (NCI)
Aug 2027T Cell Therapy of Opportunistic Cytomegalovirus Infection · Mari Dallas

Who these studies take

Of the 8 Opportunistic Infections studies recruiting now, 5 (63%) set no upper age limit and 3 (38%) stop at 75 or younger. 5 (63%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (25%) take healthy volunteers.

Recruiting studies that take each age, of 8
Age	Women	Men
10	5 (63%)	5 (63%)
18	8 (100%)	8 (100%)
30	8 (100%)	8 (100%)
40	8 (100%)	8 (100%)
50	8 (100%)	8 (100%)
65	8 (100%)	8 (100%)
75	7 (88%)	7 (88%)
85	5 (63%)	5 (63%)

Across all 41 studies, recruiting or not: 20% stop at 75 or younger and 12% at 65; 51% take children; 0% are for women only and 0% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 41 of 41. search them.